PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 863 participants.

Also called NCT04142658

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 863 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04142658
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04142658. Randomized; no masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2022-12-12 (actual). Results posted on 2024-03-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
Condition
Aortic Valve Disease
Condition
Aortic Valve Stenosis
Condition
Aortic Valve Failure
Intervention (Drug)
Apixaban 5 MG
Intervention (Drug)
Apixaban 2.5 MG
Intervention (Drug)
Warfarin
Intervention (Device)
On-X Aortic Mechanical Valve
Lead sponsor
Artivion Inc. (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct04142658
Content hash
fc9d2978f3c7aee34712b649ef36a50629f50122049d454affd4a2fdb4880d70